EVONETIX LTD (‘Evonetix’), the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced the successful close of its Series B funding. The Company has raised $30 million USD (£23 million GBP) in this round, which was led by new investor Foresite Capital. Existing investors, Draper Esprit, DCVC (Data Collective), the Morningside group, Providence Investment Company, Cambridge Consultants Ltd, Rising Tide Fund, and Civilization Ventures, also all participated in the round.

We help our customers turn biological innovation into business value.

Evonetix is the latest in a line of successful companies that trace their roots back to Cambridge Consultants. Cambridge Consultants has created more than 20 companies in its long history, with many that have changed market dynamics and disrupted whole industries. Several of these companies, including CSR, Domino and Xaar, have gone on to be listed on the London Stock Exchange. In all, Cambridge Consultants has created over £1 billion GBP worth of value and more than 3,000 jobs through its spinouts and is seen by many as a founding father of ‘the Cambridge Phenomenon’.

The new funding will be used to accelerate internal technology development, including the integration of Evonetix’s technology to enable the synthesis of DNA on a chip. The investment will fund the Company through to the introduction of its desktop DNA platform which, once fully developed, will facilitate and enable the rapidly growing field of synthetic biology, with application across industries including healthcare, pharma, biotech, food and agriculture and data storage. The investment will also support the Company’s significant recruitment plans, as it continues to increase headcount across scientific, operational and commercial staff located at Evonetix’s state-of-the-art facility at Coldhams Business Park, Cambridge, UK.

Evonetix was founded in 2015, to develop technology that enables the parallel synthesis of DNA on silicon arrays, to facilitate the fast-emerging field of synthetic biology, where there is increasing demand for high-throughput and highly accurate DNA synthesis. The Company was founded by Cambridge Consultants and Providence Investment Company Limited, and went on to close $12.3 million USD Series A funding in 2018, in addition to a grant from Innovate UK. The close of the Series B round brings the total funds raised by the Company to $46 million to date. The Company has the backing of the technology entrepreneur and venture capitalist Hermann Hauser.

The Company’s technology utilises a silicon chip, made by microelectromechanical systems (MEMS) processing, that controls the synthesis of DNA at many thousands of independently controlled reaction sites or ‘pixels’ on the chip surface in a highly parallel fashion. Following synthesis, strands are assembled on-chip into double-stranded DNA in a process that identifies and removes errors, enabling accuracy, scale and speed that is several orders of magnitude better than conventional approaches.

Dr Tim Brears, Evonetix CEO, said: “The backing of both our existing and new investors will enable us to fast track development, testing and delivery of our highly parallel desktop platform, which will be available to every researcher to accelerate their ability to use biology on a scale not possible with existing approaches.”

Jim Tananbaum, CEO and Managing Director at Foresite Capital, said: “Evonetix is developing a desktop, short latency solution to synthesise DNA. We are delighted to support the team in their mission to make biological engineering as accessible and widespread as next-generation sequencing.”

Vishal Gulati, Venture Partner, Draper Esprit, added: “The next set of breakthroughs in healthcare and synthetic biology will come from technologies that can go beyond reading DNA to writing it. Evonetix is leveraging the UK's strength in DNA research to build this unique, ground-breaking DNA synthesis platform. We’re excited to welcome Foresite Capital, one of the world's leading life-sciences investors, to support this Company to achieve the next stage of its growth and look forward to working closely with this talented team.”

Armen Vidian, Evonetix Board member and Partner at DCVC, said: “DCVC is pleased to continue its commitment to synthetic biology with its renewed investment in Evonetix. As demand grows to use synthetic biology for everything from sustaining agriculture to creating precision medicines and synthetic fuels, Evonetix will be well-positioned to meet those more complex needs with highly accurate, high throughput, long-strand DNA synthesis.”

Notes to editors

Cambridge Consultants (剑桥顾问公司)开发突破性产品,产生和授权知识产权,并为全球的客户提供商业资讯,解决与技术相关的关键问题。60多年来,公司一直致力于帮助客户转化商业机会,包括推出市场领先的产品,进入新市场,引入新技术扩大现有市场。公司拥有超过900名员工,包括工程师、科学家、数学家和设计师,遍布于英国剑桥、美国波士顿、东京和新加坡办事处,为医疗和生命科学、工业和能源、消费和零售以及通讯和基础设施等多个行业提供解决方案。欲了解更多信息,请访问: www.cambridgeconsultants.com

Cambridge Consultants是 Capgemini Invent (凯捷集团的创新、咨询和转型品牌)的子公司。Capgemini Invent帮助管理者设想和构建他们组织的未来。公司在全球设有30多个办事处和25个创意工作室,是一支拥有7000多名员工的强大团队,将战略、技术、数据科学和创意设计与深厚的行业专业知识和洞察力相结合,开发新的数字解决方案和未来的商业模式。

凯捷集团是通过技术来为客户改造和管理业务的全球领导者,而Capgemini Invent是凯捷集团不可或缺的一部分。集团的宗旨是通过技术释放人类的潜能,实现包容性和可持续的未来。它是一个及负社会责任的多元化组织,在近50个国家拥有27万名团队成员。凭借其50年的悠久历史和深厚的行业专业知识,凯捷集团受到客户的信赖,在快速发展和充满创新的云、数据、人工智能、连接、软件、数字工程和平台技术的推动下,能够满足客户从战略、设计到运营的所有业务需求。集团2020年的全球营收为160亿欧元。

获得你想要的未来 | www.capgemini.com

About Evonetix Ltd

Evonetix is reimagining biology by developing a radically different approach to gene synthesis – a highly parallel desktop platform to synthesise DNA at unprecedented accuracy and scale. The Company’s platform will place DNA synthesis in the hands of every researcher and change how DNA is accessed, made and used. This new paradigm in gene synthesis will facilitate and enable the rapidly growing field of synthetic biology. 

The proprietary Evonetix approach utilises a silicon chip, made by MEMS processing, that integrates physics with biology, and controls the synthesis of DNA at many thousands of independently controlled reaction sites or ‘pixels’ on the chip surface in a highly parallel fashion. The approach is compatible with both chemical and enzymatic DNA synthesis. Following synthesis, strands are assembled on-chip into double-stranded DNA in a process that identifies and removes errors, providing accuracy that is several orders of magnitude better than the conventional approach. 

The Evonetix DNA writer will be a desktop device, available to every researcher, and providing scalable, accurate DNA synthesis to enable biological systems to be engineered with unprecedented accuracy and scale – this is third-generation DNA synthesis. 

For further information, see www.evonetix.com 

联系方式

WE Communications

Matt
Urquhart